Cytokine levels in newly diagnosed B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at two natural proteins (IL-17A and IL-10) in the blood of people newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in South Egypt. It aims to see if these proteins relate to how active the leukemia is, which could help doctors understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with a type of leukemia called B-cell acute lymphoblastic leukemia (B-ALL).
- You cannot have had any chemotherapy or immunotherapy (drug treatment that helps your immune system fight cancer) before joining this study.
- You cannot have any other cancer besides B-ALL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures two simple blood markers (SII and CAR) in people newly diagnosed with acute lymphoblastic leukemia (ALL) who haven't started treatment yet. The goal is to see if these markers can help guide care.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
This trial looks at blood types (ABO and Rh) in people newly diagnosed with acute leukemia. It may help doctors understand if certain blood types are more common in these patients.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
This study looks at a special blood test that measures cell-free DNA (tiny pieces of genetic material) in children with acute lymphoblastic leukemia (ALL). It aims to understand how this test might help monitor the disease, and it is for newly diagnosed children who haven't started treatment yet.
This trial looks at whether a protein called IL-6 can help predict how well chemotherapy will work in people with acute myeloid leukemia (AML) who haven't been treated before. It aims to find better ways to personalize treatment.
Hear when a new Acute Lymphoblastic Leukemia, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.